4 results
To increase progression-free survival at 3 months.
Primary objective:To compare the effects of AZD7624 vs. placebo on the time to first event of moderate or severe COPD exacerbation or early drop-out related to worsening of COPD symptoms (composite endpoint) in patients with COPD on maintenance…
Does chronic nocturnal ventilatory support at home after acute respiratory failure treated by (N)IV lead to a prolongation in time to readmission to hospital due to any following exacerbations in these patients compared to medical treatment only?
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.